MAPT and synucleinopathy: Our findings reinforce the emerging concept that tau pathology is a common and functionally significant feature across synucleinopathies and suggest that therapeutic strategies targeting tau or simultaneously modulating both α-Syn and tau aggregation pathways, may more effectively mitigate neurodegeneration in synucleinopathies.